🇺🇸 FDA
Patent

US 7759335

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61PA61P1/16A61P3/04

Quick answer

US patent 7759335 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrm Discovery, Inc. expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrm Discovery, Inc.
Grant date
Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P1/16, A61P3/04, A61P3/06, A61P3/10